Triple therapy for CLL: pembrolizumab, ublituximab and umbralisib
What can we learn about CLL by studying environmental stimuli?
Myeloma 2017 day 2 highlights: MRD, targeted therapies and imaging advances
Gareth Morgan et al.
Triple therapy including nivolumab for newly diagnosed AML
The next steps for the IDH2 inhibitor drug enasidenib
Stéphane de Botton